Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis
Abstract
:1. Introduction
2. Results
2.1. Experimental Findings
2.2. Effect of ARB and Rifaximin on Liver Fibrosis
2.3. Effect of ARB and Rifaximin on Intestinal Permeability
2.4. The Inhibitory Effect of Both ARB and Rifaximin on Portal Endotoxin
2.5. Effect of ARB and Rifaximin on LPS-TLR4 Signaling
2.6. Effect of ARB and Rifaximin on Intestinal Epithelial Cell Line
3. Discussion
4. Materials and Methods
4.1. Animals and Reagents
4.2. Experimental Design
4.3. Histology and Immunohistochemistry
4.4. Quantitative Real-Time RT-PCR Analysis
4.5. Immunofluorescence Analysis
4.6. Portal Venous LBP Concentration
4.7. In Vitro Study
4.8. Statistical Analyses
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Abbreviations
ARB | Angiotensin-II receptor blocker |
CDAA | Choline-deficient l-amino acid |
CSAA | Choline-sufficient l-amino acid |
DMEM | Dulbecco’s modified Eagle’s medium |
HSC | Hepatic stellate cells |
LBP | LPS binding protein |
NASH | Nonalcoholic steatohepatitis |
PXR | Pregnane X receptor |
RFX | Rifaximin |
TJP | Tight junction protein |
VEGF | Vascular endothelial growth factor |
ZO-1 | Zonula occludens-1 |
References
- Vega, G.L. Obesity and the metabolic syndrome. Minerva Endocrinol. 2004, 29, 47–54. [Google Scholar]
- Hakan, F.; Elçin, Z. Nonalcoholic fatty liver disease as a multi-systemic disease. World J. Gastroenterol. 2016, 22, 4079–4090. [Google Scholar]
- Day, C.P.; James, O.F. Steatohepatitis: A tale of two “hits”? Gastroenterology 1998, 114, 842–845. [Google Scholar] [CrossRef]
- Tilg, H.; Moschen, A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010, 52, 1836–1846. [Google Scholar] [CrossRef] [PubMed]
- Douhara, A.; Moriya, K.; Yoshiji, H.; Noguchi, R.; Namisaki, T.; Kitade, M.; Kosuke, K.; Aihara, Y.; Nishimura, N.; Takeda, K.; et al. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. Mol. Med. Rep. 2015, 11, 1693–1700. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Musso, G.; Gambino, R.; Cassader, M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: Mechanisms and implications for metabolic disorders. Curr. Opin. Lipidol. 2010, 21, 76–83. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Szabo, G.; Bala, S.; Petrasek, J.; Gattu, A. Gut-liver axis and sensing microbes. Dig. Dis. 2010, 28, 737–744. [Google Scholar] [CrossRef] [Green Version]
- Compare, D.; Coccoli, P. Gut–liver axis: The impact of gut microbiota on nonalcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 2012, 22, 471–476. [Google Scholar] [CrossRef]
- Zeng, T.; Zhang, C.L. Critical roles of Kupffer cells in the pathogenesis of alcoholic liver disease: From basic science to clinical trials. Front. Immunol. 2016, 7, 538. [Google Scholar] [CrossRef]
- Machado, M.V.; Cortez-Pinto, H. Gut microbiota and nonalcoholic fatty liver disease. Ann. Hepatol. 2012, 11, 440–449. [Google Scholar] [CrossRef]
- Ulluwishewa, D.; Anderson, R.C.; McNabb, W.C.; Moughan, P.J.; Wells, J.M.; Roy, N.C. Regulation of tight junction permeability by intestinal bacteria and dietary components. J. Nutr. 2011, 141, 769–776. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sawada, Y.; Kawaratani, H.; Kubo, T.; Fujinaga, Y.; Fukurama, M.; Saikawa, S.; Sato, S.; Seki, S.; Takaya, H.; Okura, Y.; et al. Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis. Hepatol. Res. 2019, 49, 284–295. [Google Scholar] [CrossRef] [PubMed]
- Jin, Y.; Ren, X.; Li, G.; Li, Y.; Zhang, L.; Wang, H.; Qian, W.; Hou, X. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota. J. Gastroenterol. Hepatol. 2018, 33, 443–452. [Google Scholar] [CrossRef] [PubMed]
- Chelakkot, C.; Ghim, J.; Ryu, S.H. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp. Mol. Med. 2018, 50, 103. [Google Scholar] [CrossRef] [Green Version]
- Calanni, F.; Renzulli, C.; Barbanti, M.; Viscomi, G.C. Rifaximin: Beyond the traditional antibiotic activity. J. Antibiot. 2014, 67, 667–670. [Google Scholar] [CrossRef]
- Lyon, K.C.; Likar, E. Retrospective cross-sectional pilot study of rifaximin dosing for the prevention of recurrent hepatic encephalopathy. J. Gastroenterol. Hepatol. 2017, 32, 1548–1552. [Google Scholar] [CrossRef]
- Ng, Q.X.; Ho, C.Y.X.; Shin, D.; Venkatanarayanan, N.; Chan, H.W. A meta-analysis of the use of rifaximin to prevent travellers’ diarrhoea. J. Travel Med. 2017, 24, 1–5. [Google Scholar] [CrossRef] [Green Version]
- Kaji, K.; Takaya, H.; Saikawa, S.; Furukawa, M.; Sato, S.; Kawaratani, H.; Kitade, M.; Moriya, K.; Namisaki, T.; Akahane, T.; et al. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J. Gastroenterol. 2017, 23, 8355–8366. [Google Scholar] [CrossRef]
- Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Fukui, H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001, 34, 745–750. [Google Scholar] [CrossRef] [PubMed]
- Yoshiji, H.; Noguchi, R.; Ikenaka, Y.; Namisaki, T.; Kitade, M.; Kaji, K.; Shirai, Y.; Yoshii, J.; Yanase, K.; Yamazaki, M.; et al. Losartan, an angiotensin- II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res. Notes 2009, 2, 70. [Google Scholar] [CrossRef] [Green Version]
- Yoshiji, H.; Noguchi, R.; Ikenaka, Y.; Kaji, K.; Aihara, Y.; Shirai, Y.; Yoshii, J.; Yanase, K.; Fukui, H. Cocktail therapy with a combination of interferon, ribavirin and angiotensin-II type 1 receptor blocker attenuates murine liver fibrosis development. Int. J. Mol. Med. 2011, 28, 81–88. [Google Scholar] [CrossRef] [PubMed]
- Shirai, Y.; Yoshiji, H.; Noguchi, R.; Kaji, K.; Aihara, Y.; Douhara, A.; Moriya, K.; Namisaki, T.; Kawaratani, H.; Fukui, H. Cross talk between Toll like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2013, 28, 723–730. [Google Scholar] [CrossRef] [PubMed]
- Seki, E.; De Minicis, S.; Osterreicher, C.H.; Kluwe, J.; Osawa, Y.; Brenner, D.A.; Schwabe, R.F. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 2007, 13, 1324–1332. [Google Scholar] [CrossRef] [PubMed]
- Yoshiji, H.; Kuriyama, S.; Noguchi, R.; Ikenaka, Y.; Kitade, M.; Kaji, K.; Yoshii, J.; Yanase, K.; Yamazaki, M.; Asada, K.; et al. Angiotensin-II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development. Hepatol. Res. 2006, 36, 124–129. [Google Scholar] [CrossRef]
- Bjornsson, E. The clinical aspects of non-alcoholic fatty liver disease. Minerva Gastroenterol. Dietol. 2008, 54, 7–18. [Google Scholar]
- Friedman, S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134, 1655–1669. [Google Scholar] [CrossRef] [Green Version]
- Yang, L.; Liu, B.; Zheng, J.; Huang, J.; Zhao, Q.; Liu, J.; Su, Z.; Wang, M.; Cui, Z.; Wang, T.; et al. Rifaximin alters intestinal microbiota and prevents progression of ankylosing spondylitis in mice. Front. Cell Infect. Microbiol. 2019, 9, 44. [Google Scholar] [CrossRef] [Green Version]
- Mencarelli, A.; Renga, B.; Palladino, G.; Claudio, D.; Ricci, P.; Distrutti, E.; Barbanti, M.; Baldelli, F.; Fiorucci, S. Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Eur. J. Pharmacol. 2011, 668, 317–324. [Google Scholar] [CrossRef]
- Piche, T. Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol. Motil. 2014, 26, 296–302. [Google Scholar] [CrossRef]
- Suzuki, T. Regulation of intestinal epithelial permeability by tight junctions. Cell. Mol. Life Sci. 2013, 70, 631–659. [Google Scholar] [CrossRef]
- Miele, L.; Valenza, V.; La Torre, G.; Montalto, M.; Cammarota, G.; Ricci, R.; Mascianà, R.; Forgione, A.; Gabrieli, M.L.; Perotti, G.; et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49, 1877–1887. [Google Scholar] [CrossRef] [PubMed]
- Rivera, C.A.; Adegboyega, P.; van Rooijen, N.; Tagalicud, A.; Allman, M.; Wallace, M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007, 47, 571–579. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Du Plessis, J.; Vanheel, H.; Janssen, C.E.; Roos, L.; Slavik, T.; Stivaktas, P.I.; Nieuwoudt, M.; van Wyk, S.G.; Vieira, W.; Pretorius, E.; et al. Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J. Hepatol. 2013, 58, 1125–1132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Petrasek, J.; Csak, T.; Szabo, G. Toll-like receptors in liver disease. Adv. Clin. Chem. 2013, 59, 155–201. [Google Scholar]
- Kliewer, S.A.; Goodwin, B.; Willson, T.M. The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism. Endocr. Rev. 2002, 23, 687–702. [Google Scholar] [CrossRef] [Green Version]
- Ostberg, T.; Bertilsson, G.; Jendeberg, L.; Berkenstam, A.; Uppenberg, J. Identification of residues in the PXR ligand binding domain critical for species specific and constitutive activation. Eur. J. Biochem. 2002, 269, 4896–4904. [Google Scholar] [CrossRef]
- Gu, X.; Ke, S.; Liu, D.; Sheng, T.; Thomas, P.E.; Rabson, A.B.; Gallo, M.A.; Xie, W.; Tian, Y. Role of NF-kappaB in regulation of PXR-mediated gene expression: A mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J. Biol. Chem. 2006, 281, 17882–17889. [Google Scholar] [CrossRef] [Green Version]
- Cheng, J.; Shah, Y.M.; Ma, X.; Pang, X.; Tanaka, T.; Kodama, T.; Krausz, K.W.; Gonzalez, F.J. Therapeutic role of rifaximin in inflammatory bowel disease: Clinical implication of human pregnane x receptor activation. J. Pharmacol. Exp. Ther. 2010, 335, 32–41. [Google Scholar] [CrossRef] [Green Version]
- Okura, Y.; Namisaki, T.; Moriya, K.; Kitade, M.; Takeda, K.; Kaji, K.; Noguchi, R.; Nishimura, N.; Seki, K.; Kawaratani, H.; et al. Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis. Hepatol Res. 2017, 47, 1317–1328. [Google Scholar] [CrossRef]
- Kitagawa, R.; Kon, K.; Uchiyama, A.; Arai, K.; Yamashina, S.; Kuwahara-Arai, K.; Kirikae, T.; Ueno, T.; Ikejima, K. Rifaximin prevents ethanol-induced liver injury in obese KK-A(y) mice through modulation of small intestinal microbiota signature. Am. J Physiol. Gastrointest. Liver Physiol. 2019, 317, G707–G715. [Google Scholar] [CrossRef]
- Kawaratani, H.; Tsujimoto, T.; Kitazawa, T.; Kitade, M.; Yoshiji, H.; Uemura, M.; Fukui, H. Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet. World J. Gastroenterol. 2008, 14, 6655–6661. [Google Scholar] [CrossRef] [PubMed]
- Ishizaki, K.; Iwaki, T.; Kinoshita, S.; Koyama, M.; Fukunari, A.; Tanaka, H.; Tsurufuji, M.; Sakata, K.; Maeda, Y.; Imada, T.; et al. Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production. Eur. J. Pharmacol. 2008, 578, 57–64. [Google Scholar] [CrossRef] [PubMed]
- Noguchi, R.; Yoshiji, H.; Ikenaka, Y.; Kaji, K.; Aihara, Y.; Shirai, Y.; Namisaki, T.; Kitade, M.; Douhara, A.; Moriya, K.; et al. Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis. Hepatol. Res. 2013, 43, 765–774. [Google Scholar] [CrossRef] [PubMed]
- Kaji, K.; Yoshiji, H.; Ikenaka, Y.; Noguchi, R.; Aihara, Y.; Douhara, A.; Moriya, K.; Kawaratani, H.; Shirai, Y.; Yoshii, J.; et al. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J. Gastroenterol. 2014, 49, 481–491. [Google Scholar] [CrossRef] [PubMed]
Characteristic | Control | CDAA | ARB | RFX | ARB+RFX |
---|---|---|---|---|---|
Body weight (g) | 338.0 ± 16.4 | 281.7 ± 14.4 † | 265.0 ± 17.8 †† | 271.8 ± 24.0 †† | 272.2 ± 16.2 †† |
Liver weight (g) | 11.0 ± 0.9 | 12.4 ± 1.2 | 11.4 ± 1.4 | 13.1 ± 1.8 | 12.1 ± 0.9 |
Liver weight (%body) | 3.2 ± 0.2 | 4.4 ± 0.2 † | 4.3 ± 0.3 † | 4.8 ± 0.5 † | 4.5 ± 0.2 † |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Fujinaga, Y.; Kawaratani, H.; Kaya, D.; Tsuji, Y.; Ozutsumi, T.; Furukawa, M.; Kitagawa, K.; Sato, S.; Nishimura, N.; Sawada, Y.; et al. Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. Int. J. Mol. Sci. 2020, 21, 5589. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21155589
Fujinaga Y, Kawaratani H, Kaya D, Tsuji Y, Ozutsumi T, Furukawa M, Kitagawa K, Sato S, Nishimura N, Sawada Y, et al. Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences. 2020; 21(15):5589. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21155589
Chicago/Turabian StyleFujinaga, Yukihisa, Hideto Kawaratani, Daisuke Kaya, Yuki Tsuji, Takahiro Ozutsumi, Masanori Furukawa, Koh Kitagawa, Shinya Sato, Norihisa Nishimura, Yasuhiko Sawada, and et al. 2020. "Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis" International Journal of Molecular Sciences 21, no. 15: 5589. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21155589